ETC
DAWN

Exchange Traded Concepts’s Day One Biopharmaceuticals DAWN Stock Holding History

Exchange Traded Concepts’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,693
Closed -$117K – 1429
2025
Q1 		$117K Buy
14,693
+2,407
+20% +$25.9K ﹤0.01% 1101
2024
Q4 		$156K Hold
12,286
– – ﹤0.01% 1048
2024
Q3 		$171K Sell
12,286
-3,031
-20% -$43.2K ﹤0.01% 1011
2024
Q2 		$211K Sell
15,317
-4,763
-24% -$69.7K 0.01% 870
2024
Q1 		$332K Buy
20,080
+10,008
+99% +$150K 0.01% 766
2023
Q4 		$147K Buy
10,072
+2,554
+34% +$31K ﹤0.01% 835
2023
Q3 		$92.2K Sell
7,518
-2,895
-28% -$37.8K ﹤0.01% 927
2023
Q2 		$124K Buy
+10,413
New +$136K ﹤0.01% 897

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exchange Traded Concepts's DAWN Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Day One Biopharmaceuticals (DAWN) in Q2 2025, closing a stake of 14,693 shares — an estimated $117K sold.

Exchange Traded Concepts first reported a position in DAWN in Q2 2023 and held it in 8 quarters. The position peaked at $332K in Q1 2024. 174 funds tracked by Wall St. Rank hold DAWN as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Day One Biopharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 14,693 Day One Biopharmaceuticals shares in Q2 2025, an estimated $117K.
  • Exchange Traded Concepts first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Day One Biopharmaceuticals position peaked at $332K in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.